Search results
Results from the WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The term human blood group systems is defined by the International Society of Blood Transfusion (ISBT) as systems in the human species where cell-surface antigens—in particular, those on blood cells—are "controlled at a single gene locus or by two or more very closely linked homologous genes with little or no observable recombination between them", [1] and include the common ABO and Rh ...
Anti-Di a (the antibody to Di a) can cause severe hemolytic disease of the newborn and severe transfusion reaction. Anti-Di b usually causes milder reactions. [2] The Wright blood system is another pair of types, Wright a (Wr a) and Wright b (Wr b), also differing by one amino acid on the AE1 glycoprotein and one nucleotide on the SLC4A1 gene.
In the antibody screening procedure, an individual's plasma is added to a panel of two or three sets of red blood cells which have been chosen to express most clinically significant blood group antigens. Only group O cells are used in antibody screening, as otherwise the cells would react with the naturally occurring ABO blood group antibodies.
Anti-M and anti-N are generally clinically insignificant. Anti-S, anti-s and anti-U antibodies are acquired following exposure (via pregnancy or past transfusion with blood products) and are warm-reacting IgG-class antibodies. [7] Anti-S, anti-s and anti-U are usually clinically significant.
Anti-Fy a is a common antibody while anti-Fy b is approximately 20 times less common., [106] [107] They are reactive at body temperature and are therefore clinically significant, although they do not typically bind complement. Antibodies are acquired through exposure (pregnancy or history of blood transfusion) and subsequent alloimmunization.
The same study also identified 18 rare alleles, which generally have a weaker glycosylation activity. People with weak alleles of A can sometimes express anti-A antibodies, though these are usually not clinically significant as they do not stably interact with the antigen at body temperature. [41]
The principle of monoclonal antibody production, called hybridoma technology, was published in 1975 by Georges Köhler and César Milstein, [30] who were awarded the 1984 Medicine Nobel Prize for their discovery together with Niels Kaj Jerne. [31] Muromonab-CD3 was the first monoclonal antibody to be approved for clinical use in humans, in 1986 ...